Safety and Efficacy of Biodegradable Polymer-Coated Sirolimus-Eluting Stents in “Real-World” Practice

• Published in: JACC. Cardiovascular interventions 2009-04, Vol.2 (4), p.303-309
• Main Authors: Han, Yaling, MD, Jing, Quanmin, MD, Xu, Bo, MBBS, Yang, Lixia, MD, Liu, Huiliang, MD, Shang, Xiaoming, MD, Jiang, Tieming, MD, Li, Zhanquan, MD, Zhang, Hua, MD, Li, Hui, MD, Qiu, Jian, MD, Liu, Yingfeng, MD, Li, Yi, MD, Chen, Xuezhi, MD, Gao, Runlin, MD
• Format: Article
• Language: English
• Subjects: biodegradable polymer; Cardiovascular; coronary heart disease; drug-eluting stents; sirolimus
• ISSN: 1936-8798; 1876-7605
• DOI: 10.1016/j.jcin.2008.12.013

Safety and Efficacy of Biodegradable Polymer-Coated Sirolimus-Eluting Stents in “Real-World” Practice: 18-Month Clinical and 9-Month Angiographic Outcomes Yaling Han, Quanmin Jing, Bo Xu, Lixia Yang, Huiliang Liu, Xiaoming Shang, Tieming Jiang, Zhanquan Li, Hua Zhang, Hui Li, Jian Qiu, Yingfeng Liu, Yi Li, Xuezhi Chen, Runlin Gao, for the CREATE (Multi-Center Registry of Excel Biodegradable Polymer Drug-Eluting Stents) Investigators A total of 2,077 “real-world” patients treated with Excel biodegradable polymer-coated sirolimus-eluting stents were enrolled in this multicenter registry. Of discharged patients, 80.5% discontinued clopidogrel treatment at 6 months. At 18-month follow-up, the major adverse cardiac events rate was 3.1% and overall incidence of stent thrombosis was 0.87%. Angiographic follow-up, performed in 974 (31.6%) lesions from 653 patients (31.7%), revealed a mean in-stent late lumen loss of 0.21 ± 0.39 mm. Binary restenosis rates were 3.8% in-stent and 6.7% in-segment. Use of a biodegradable polymer-coated sirolimus-eluting stent with 6 months of dual antiplatelet treatment appears safe and effective in real-world settings.